Deep Magnetic Stimulation Therapy
Katie's Way is revolutionizing depression treatment. Have you been diagnosed with major depressive disorder (MDD)? Have you tried one or more antidepressant medications without relief? If you're struggling to overcome depression, Deep TMS therapy can help you achieve wellbeing.
What is Deep TMS therapy?
Transcranial Magnetic Stimulation, or TMS, is an FDA approved, non-invasive treatment option that offers long-term relief for major depression. This revolutionary treatment uses magnetic fields to stimulate areas of the brain that control mood and are under active in people with depression.
How Does Deep TMS Work?
The treatment fully integrates into your routine. During each session, you are comfortably seated on a chair and a cushioned helmet is placed over your head. The helmet uses magnetic fields to stimulate the targeted brain area and improve depressive symptoms. The procedure requires daily sessions for 20 minutes for 4-6 weeks. As the treatment does not require hospitalization or anesthesia, and entails no memory loss, you can return to your normal return after each treatment.
Deep TMS Therapy an Effective, Well Tolerated and Non-Invasive.
WIth each therapy session lasting approximately 20 minutes, the treatment can fit easily into your schedule. The treatment has minimal side effects1, and is covered by most private payers. Anyone 18 and older is eligible receive TMS.
Frequently Asked Questions
Who Can recieve TMS?
BrainsWay is approved for patients aged 18 or older who have been diagnosed with major depressive disorder (MDD).
How effective is TMS?
In real-life clinical settings2, the treatment was proven to be effective for 3 out of 4 patients, with a 51% remission rate and 75% response rate.
I have already tried other medications. How is this any better?
Studies have shown the treatment to be effective for patients with depression, no matter how many other medications were tried in the current depressive episode.
Has TMS been tested?
BrainsWay uses Deep TMS technology, which has been tested in over 60 clinical studies for various indications in leading institutions worldwide. The FDA has cleared this technology for clinical use in Major Depressive Disorder and it is currently available in the US, Europe and South America3. Over 15,000 patients have already been treated with BrainsWay.
What should I expect during treatment?
The treatment integrates seamlessly into your routine. During each session, you are comfortably seated on a chair and a cushioned helmet is placed over your head. The helmet uses magnetic fields to stimulate the targeted brain area and improve depressive symptoms. The procedure requires daily sessions of 20 minutes for 4-6 weeks. As the treatment does not require hospitalization or anesthesia, and entails no memory loss and no systemic side effects, you can return to your normal routine after each session.
Is treatment uncomfortable?
BrainsWay is a non-invasive procedure, which eliminates the need for hospitalization. Patients may experience minor side effects such as headaches or minor pain at the site of the treatment. However, this is usually brief and ceases after the first few sessions.
720 Poyntz Avenue
Manhattan, KS, 66502
1 Safety Information: Patients should consult with their doctor before undergoing BrainsWayD The most common side effects include headaches and application site pain or discomfort. There is also a very rare risk of seizure associated with the treatment. Patients with metal in or around the head such as in metal plates, implants and stents, should not undergo Deep TMS treatment.
2 Remission Response Rates: In the multicenter trial that led to BrainsWay's FDA clearance for MDD, 1 in 3 medication-resistant patients achieved full remission and 38.4% achieved a positive response. Real life settings have shown significantly better results. Data on file.
3 Indication: BrainsWayD is indicated by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. K 122288.